{"id":"placebo-to-salbutamol","safety":{"commonSideEffects":[{"rate":"5-10","effect":"Tremor"},{"rate":"5-10","effect":"Headache"},{"rate":"5-10","effect":"Nervousness"},{"rate":"1-5","effect":"Palpitations"},{"rate":"1-5","effect":"Tachycardia"}]},"_chembl":{"chemblId":"CHEMBL714","moleculeType":"Small molecule","molecularWeight":"239.31"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Salbutamol binds to and activates beta-2 adrenergic receptors on airway smooth muscle cells, triggering a cascade that increases intracellular cAMP levels. This leads to smooth muscle relaxation and rapid bronchodilation, relieving airway obstruction. It is a short-acting bronchodilator used for acute relief of bronchoconstriction in asthma and COPD.","oneSentence":"Salbutamol is a beta-2 adrenergic agonist that relaxes airway smooth muscle by activating beta-2 receptors, causing bronchodilation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:28:52.275Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute bronchospasm relief in asthma"},{"name":"Acute bronchospasm relief in chronic obstructive pulmonary disease (COPD)"}]},"trialDetails":[{"nctId":"NCT06676319","phase":"PHASE2","title":"Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma","status":"RECRUITING","sponsor":"Sanofi","startDate":"2024-11-07","conditions":"Asthma","enrollment":1147},{"nctId":"NCT06664619","phase":"PHASE3","title":"A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma","status":"RECRUITING","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2024-12-12","conditions":"Asthma","enrollment":724},{"nctId":"NCT07037511","phase":"NA","title":"Effects of Salbutamol in Athletes and Implications for Screening and Sports","status":"RECRUITING","sponsor":"University of British Columbia","startDate":"2025-10-30","conditions":"Asthma, Healthy, Effect of Drug","enrollment":64},{"nctId":"NCT06502366","phase":"PHASE3","title":"A Study to Investigate the Effect on Lung Function of BDA Formulated With a Next Generation Propellant Compared With an Approved Asthma Treatment (BDA With HFA Propellant) in Participants With Asthma","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2024-07-22","conditions":"Asthma","enrollment":422},{"nctId":"NCT05776927","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of QVM149 (Indacaterol Acetate / Glycopyrronium Bromide / Mometasone Furoate) Versus Salmeterol Xinafoate/Fluticasone Propionate in Children From 12 Years to Less Than 18 Years of Age With Asthma.","status":"NOT_YET_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2026-05-29","conditions":"Asthma","enrollment":304},{"nctId":"NCT07378605","phase":"NA","title":"Effect of Intraoperative Salbutamol Administration on Mechanical Power and Respiratory Mechanics in Obese Patients Undergoing Laparoscopic Bariatric Surgery","status":"NOT_YET_RECRUITING","sponsor":"Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital","startDate":"2026-01-01","conditions":"Bariatric Surgery","enrollment":66},{"nctId":"NCT05527704","phase":"PHASE3","title":"the Inhaled β2-adrenergic Receptor Agonist for Transient Tachypnoea of the Newborn (the REFSAL Trial)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Medical University of Warsaw","startDate":"2021-12-31","conditions":"TTN, Respiratory Failure, PPHN","enrollment":608},{"nctId":"NCT06027606","phase":"PHASE1","title":"Cardiovascular Consequences of Inhaled Short-acting Beta-agonist Use","status":"COMPLETED","sponsor":"University of Alberta","startDate":"2023-09-01","conditions":"Healthy","enrollment":81},{"nctId":"NCT06433921","phase":"PHASE1","title":"A Study to Compare the Relative Potency of Salbutamol Administered Via Metered Dose Inhalers (MDI) Containing Propellants HFA-152a to HFA-134a in Mild Asthmatics Aged 18 to 65 Inclusive","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2024-08-14","conditions":"Asthma, Mild Asthma","enrollment":84},{"nctId":"NCT06040268","phase":"PHASE1, PHASE2","title":"Advair HFA in Healthy and HAPE Predisposed Subjects","status":"RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2023-12-12","conditions":"Altitude Edema","enrollment":60},{"nctId":"NCT04655508","phase":"PHASE3","title":"Efficacy of Fluticasone Propionate Associated With Salmeterol Using Inhalation Chamber Versus Placebo to Improve the Respiratory Function in Children Over Six Years of Age Who Underwent Allogeneic Hematopoietic Stem Cell Transplantation With a Decline of FEV1 ≥10% From Pre Transplantation","status":"TERMINATED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2021-05-21","conditions":"Stem Cell Transplant Complications, Respiratory Disease, Bronchiolitis Obliterans","enrollment":35},{"nctId":"NCT05366764","phase":"PHASE1","title":"First-in-human Study of SAR443765 in Healthy Participants and in Asthmatic Participants","status":"COMPLETED","sponsor":"Sanofi","startDate":"2022-06-08","conditions":"Asthma","enrollment":36},{"nctId":"NCT06644924","phase":"PHASE2","title":"A Study Evaluating the Effect of Inhaled PT007(AS MDI) Versus Placebo MDI and Ventolin Evohaler on Lung Function in Adult Participants With Asthma","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2025-02-10","conditions":"Asthma","enrollment":118},{"nctId":"NCT04643158","phase":"PHASE2","title":"Efficacy and Safety of Inhaled AZD1402 Administered for Four Weeks in Adults With Asthma on Medium-to-High Dose Inhaled Corticosteroids","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2021-03-12","conditions":"Asthma","enrollment":72},{"nctId":"NCT06245551","phase":"PHASE3","title":"A Study to Investigate the Effects of PT027 (Budesonide/Albuterol Sulfate) Metered-dose Inhaler Compared With Placebo on Exercise-Induced Bronchoconstriction in Adult Patients With Asthma","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2023-12-22","conditions":"Asthma, Exercise-Induced","enrollment":64},{"nctId":"NCT07112456","phase":"PHASE2","title":"Nebulized Ketamine Plus Standard Care vs. Standard Care Alone in Moderate to Severe Asthma Exacerbations","status":"NOT_YET_RECRUITING","sponsor":"Oman Medical Speciality Board","startDate":"2026-09-01","conditions":"Asthma Acute, Asthma Attack, Asthma Exacerbations","enrollment":100},{"nctId":"NCT06154304","phase":"PHASE3","title":"BE Study of Albuterol Sulfate Inhalation Aerosol 90 mcg Per Actuation in Patients With Stable Mild Asthma","status":"COMPLETED","sponsor":"Cipla Ltd.","startDate":"2023-12-06","conditions":"Bronchial Asthma","enrollment":120},{"nctId":"NCT05819541","phase":"PHASE2","title":"Treating Exacerbations of Asthma With Oral Montelukast in Children","status":"RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2023-10-20","conditions":"Status Asthmaticus","enrollment":90},{"nctId":"NCT05099107","phase":"NA","title":"Changes of Motor Function Tests in Congenital Myopathy Subjects Treated With Oral Salbutamol as Compared to no Treatment","status":"COMPLETED","sponsor":"Vastra Gotaland Region","startDate":"2021-10-25","conditions":"Congenital Myopathy, Neuromuscular Diseases, Musculoskeletal Diseases","enrollment":18},{"nctId":"NCT05987371","phase":"PHASE2","title":"A Clinical Trial of TQC3721 Suspension for Inhalation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease.","status":"COMPLETED","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2023-08-23","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":75},{"nctId":"NCT06655012","phase":"NA","title":"Salmeterol Effect on Exercise Performance","status":"RECRUITING","sponsor":"University of Copenhagen","startDate":"2024-10-31","conditions":"Healthy","enrollment":36},{"nctId":"NCT06654986","phase":"NA","title":"Muscle Anabolic Response to β2-adrenergic Stimulation With Increased Amino Acid Availability.","status":"RECRUITING","sponsor":"University of Copenhagen","startDate":"2024-10-31","conditions":"Healthy","enrollment":36},{"nctId":"NCT03522831","phase":"NA","title":"CF Bronchodilation","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of British Columbia","startDate":"2018-05-01","conditions":"Lung Diseases, Cystic Fibrosis","enrollment":20},{"nctId":"NCT02797275","phase":"PHASE4","title":"Secondhand Smoke Respiratory Health Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of California, San Francisco","startDate":"2016-06-06","conditions":"Secondhand Smoke, Air Trapping, Tobacco","enrollment":107},{"nctId":"NCT04912596","phase":"NA","title":"Pharmacodynamic Equivalence of the Test and Reference Metered Dose Inhalers (MDIs) Containing Albuterol Sulfate in Adult Patients With Stable Mild Asthma","status":"RECRUITING","sponsor":"Intech Biopharm Ltd.","startDate":"2022-08-15","conditions":"Mild Asthma","enrollment":148},{"nctId":"NCT05977699","phase":"PHASE4","title":"Reversibility of Methacholine Induced Bronchoconstriction","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Saskatchewan","startDate":"2024-01-12","conditions":"Asthma","enrollment":20},{"nctId":"NCT06618105","phase":"PHASE3","title":"Bronchoprovocation Study to Demonstrate the Pharmacodynamic Bioequivalence of Albuterol Sulfate HFA Inhalation Aerosol (E.Q. 90 mcg of Albuterol Base/Inh) of Macleods Pharmaceuticals Ltd","status":"NOT_YET_RECRUITING","sponsor":"Macleods Pharmaceuticals Ltd","startDate":"2024-10-15","conditions":"Mild Asthma","enrollment":144},{"nctId":"NCT03562195","phase":"PHASE3","title":"A Safety and Efficacy Study of Mepolizumab in Subjects With Severe Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-08-29","conditions":"Asthma","enrollment":300},{"nctId":"NCT00127166","phase":"PHASE3","title":"Two Investigational Drugs in the Prevention of Airway Constriction Brought on by Exercise in Participants With Asthma (0476-911)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-12","conditions":"Exercise Induced Asthma","enrollment":154},{"nctId":"NCT00739297","phase":"PHASE1","title":"The Safety and Effectiveness of MK0476 (Montelukast) in Patients With Chronic Asthma (0476-388)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2008-07","conditions":"Chronic Asthma","enrollment":68},{"nctId":"NCT02508311","phase":"PHASE4","title":"Albuterol to Improve Respiratory Strength in SCI","status":"TERMINATED","sponsor":"VA Office of Research and Development","startDate":"2016-06-01","conditions":"Spinal Cord Injury, Respiratory Muscle Weakness","enrollment":1},{"nctId":"NCT05550402","phase":"NA","title":"Role of Parasympathetic Activity in Mild to Severe Asthma With Fixed Airway Obstruction (PARASMA Study)","status":"UNKNOWN","sponsor":"Hat Yai Medical Education Center","startDate":"2024-02-17","conditions":"Asthma, Airway Obstruction, Airway Remodeling","enrollment":60},{"nctId":"NCT02889809","phase":"PHASE4","title":"Effects of a Orally Inhaled Fluticasone Furoate on Growth Velocity in Prepubertal, Paediatric Subjects With Asthma Over a Year","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-07-10","conditions":"Asthma","enrollment":477},{"nctId":"NCT03460704","phase":"PHASE3","title":"Trial in Non-cystic Fibrosis Bronchiectasis Patients With Chronic Lung Infections Treated With Colistimethate Sodium.","status":"TERMINATED","sponsor":"Zambon SpA","startDate":"2018-01-29","conditions":"Non Cystic Fibrosis Bronchiectasis","enrollment":287},{"nctId":"NCT01880723","phase":"NA","title":"Utilizing Exhaled Breathe Condensate Collection to Study Ion Regulation in Cystic Fibrosis","status":"COMPLETED","sponsor":"University of Arizona","startDate":"2009-05","conditions":"Cystic Fibrosis, Healthy","enrollment":32},{"nctId":"NCT03093974","phase":"PHASE3","title":"Efficacy and Safety of Inhaled CMS in Bronchiectasis Subjects With Chronic P. Aeruginosa Infection. (PROMIS-I)","status":"COMPLETED","sponsor":"Zambon SpA","startDate":"2017-06-06","conditions":"Non Cystic Fibrosis Bronchiectasis","enrollment":377},{"nctId":"NCT05932316","phase":"NA","title":"Evaluating Bronchodilator Response in Patients With Bronchiectasis","status":"UNKNOWN","sponsor":"Rambam Health Care Campus","startDate":"2023-05-20","conditions":"Bronchiectasis, Cystic Fibrosis, Primary Ciliary Dyskinesia","enrollment":96},{"nctId":"NCT00819637","phase":"PHASE4","title":"A Pilot Study to Determine the Most Effective Dose of Arformoterol for Treating Acute Asthmatic Patients","status":"TERMINATED","sponsor":"Henry Ford Health System","startDate":"2009-01","conditions":"Acute Asthma","enrollment":2},{"nctId":"NCT03847896","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of Budesonide/Albuterol Metered Dose Inhaler (BDA MDI/PT027) Used 4 Times Daily in Adults and Children 4 Years of Age or Older With Asthma","status":"COMPLETED","sponsor":"Bond Avillion 2 Development LP","startDate":"2019-03-20","conditions":"Asthma","enrollment":1001},{"nctId":"NCT04565847","phase":"PHASE2","title":"The Effects of Salbutamol on Mannitol Induced Cough Responses in Healthy Controls","status":"COMPLETED","sponsor":"McMaster University","startDate":"2020-11-30","conditions":"Cough","enrollment":20},{"nctId":"NCT03387852","phase":"PHASE2","title":"Evaluation of SAR440340 and as Combination Therapy With Dupilumab in Moderate-to-Severe Asthma Participants","status":"COMPLETED","sponsor":"Sanofi","startDate":"2018-03-12","conditions":"Asthma","enrollment":296},{"nctId":"NCT00583778","phase":"NA","title":"A Comparison of Levalbuterol Plus Ipratropium With Levalbuterol Alone in the Treatment of Acute Asthma Exacerbation","status":"COMPLETED","sponsor":"MetroHealth Medical Center","startDate":"2004-08","conditions":"Asthma","enrollment":141},{"nctId":"NCT02178566","phase":"PHASE2","title":"Pulmonary Rehab in Chronic Obstructive Pulmonary Disease (COPD): Response to Tyvaso","status":"TERMINATED","sponsor":"Inova Health Care Services","startDate":"2015-08","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":1},{"nctId":"NCT02573233","phase":"PHASE2","title":"Evaluation of Dupilumab's Effects on Airway Inflammation in Patients With Asthma","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-01-27","conditions":"Asthma","enrollment":42},{"nctId":"NCT02948959","phase":"PHASE3","title":"Evaluation of Dupilumab in Children With Uncontrolled Asthma","status":"COMPLETED","sponsor":"Sanofi","startDate":"2017-04-21","conditions":"Asthma","enrollment":408},{"nctId":"NCT04402658","phase":"NA","title":"Can Anti-asthmatic Medication Improve Sprint Performance in Healthy Endurance Athletes?","status":"WITHDRAWN","sponsor":"Norwegian School of Sport Sciences","startDate":"2022-08-01","conditions":"Sports Drug Abuse","enrollment":""},{"nctId":"NCT02245672","phase":"PHASE3","title":"MGR001 / Advair Diskus Local Equivalence Study in Asthma","status":"COMPLETED","sponsor":"Mylan Pharma UK Ltd.","startDate":"2014-10","conditions":"Asthma","enrollment":1128},{"nctId":"NCT01056159","phase":"PHASE1","title":"A Cumulative Dose Study to Evaluate the Safety and Efficacy of Albuterol in a Dry Powder Inhaler and an HFA MDI (Hydrofluoroalkane Metered Dose Inhaler)","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2010-01","conditions":"Asthma","enrollment":47},{"nctId":"NCT00245570","phase":"PHASE3","title":"Montelukast Compared With Placebo and Salmeterol in Exercise-Induced Bronchoconstriction (0476-316)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-12","conditions":"Asthma, Exercise-Induced","enrollment":47},{"nctId":"NCT01899144","phase":"PHASE2","title":"Efficacy and Safety Comparison of Albuterol Spiromax® and ProAir® Hydrofluoroalkane (HFA) in Pediatric Patients","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2013-07","conditions":"Asthma","enrollment":61},{"nctId":"NCT04234464","phase":"PHASE3","title":"A Study to Assess the Efficacy of Budesonide/Albuterol Metered-dose Inhaler (BDA MDI/PT027) on Exercise-induced Bronchoconstriction in Adults and Adolescents With Asthma","status":"COMPLETED","sponsor":"Bond Avillion 2 Development LP","startDate":"2020-01-15","conditions":"Exercise Induced Bronchospasm","enrollment":60},{"nctId":"NCT02139644","phase":"PHASE3","title":"Study of Fluticasone Propionate MDPI Compared With Fluticasone/Salmeterol MDPI in Adolescent and Adult Patients With Persistent Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2014-06","conditions":"Asthma","enrollment":787},{"nctId":"NCT00577655","phase":"PHASE3","title":"Albuterol HFA MDI in Pediatric Participants With Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2007-08","conditions":"Asthma","enrollment":103},{"nctId":"NCT02141854","phase":"PHASE3","title":"Efficacy and Safety Study of FP MDPI Compared With FS MDPI in Adolescent and Adult Patients With Persistent Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2014-06","conditions":"Asthma","enrollment":882},{"nctId":"NCT02031640","phase":"PHASE3","title":"A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Participants >=12 Years Old With Persistent Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2013-12","conditions":"Asthma","enrollment":1113},{"nctId":"NCT02040779","phase":"PHASE3","title":"A 12-week Safety and Efficacy Study of Beclomethasone Dipropionate (80 and 160 mcg/Day) Delivered Via Breath-Actuated Inhaler (BAI) in Patients >=12 Years Old With Persistent Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2013-12-26","conditions":"Persistent Asthma","enrollment":273},{"nctId":"NCT02126839","phase":"PHASE3","title":"A Chronic-Dose Safety and Efficacy Study of Albuterol Multi-Dose Dry Powder Inhaler in Pediatric Asthmatics","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2014-05","conditions":"Asthma","enrollment":186},{"nctId":"NCT01058863","phase":"PHASE2","title":"A Dose-ranging Study to Evaluate Albuterol and Hydrofluoroalkane in Subjects Ages 12 and Older With Persistent Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2010-02","conditions":"Asthma","enrollment":72},{"nctId":"NCT02040766","phase":"PHASE3","title":"A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Participants Ages 4-11 Years Old With Persistent Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2013-12","conditions":"Asthma","enrollment":628},{"nctId":"NCT02513160","phase":"PHASE3","title":"Study to Assess the Efficacy and Safety of Beclomethasone Dipropionate in Adolescent and Adult Patients 12 Years of Age and Older With Persistent Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2015-09-30","conditions":"Persistent Asthma","enrollment":713},{"nctId":"NCT00674817","phase":"PHASE2","title":"An Investigation Of The Interaction Of GSK961081 With Inhaled Beta-Agonist And Anti-Muscarinic Drugs.","status":"COMPLETED","sponsor":"Theravance Biopharma","startDate":"2008-04-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":45},{"nctId":"NCT03468790","phase":"PHASE3","title":"Anti-IgE Monoclonal Antibody Treatment in Patients With Allergic Asthma.","status":"COMPLETED","sponsor":"Shanghai Biomabs Pharmaceutical Co., Ltd.","startDate":"2018-05-09","conditions":"Asthma, Allergic","enrollment":393},{"nctId":"NCT02252302","phase":"NA","title":"Exercise in Air Pollution and Lung Health in Asthmatics","status":"COMPLETED","sponsor":"University of British Columbia","startDate":"2015-05","conditions":"Exercise-induced Bronchoconstriction, Air Pollution","enrollment":20},{"nctId":"NCT03756883","phase":"PHASE3","title":"Therapeutic Equivalence of Two Formulations of Fluticasone Propionate and Salmeterol Inhalation Powder in Subjects With Asthma","status":"COMPLETED","sponsor":"Actavis Inc.","startDate":"2018-12-03","conditions":"Asthma","enrollment":999},{"nctId":"NCT01742702","phase":"","title":"HaemoDYNAMICs in Primary and Secondary Hypertension","status":"UNKNOWN","sponsor":"Tampere University","startDate":"2006-05-25","conditions":"Primary Hypertension, Secondary Hypertension, Aortic Stenosis","enrollment":2000},{"nctId":"NCT04584034","phase":"PHASE4","title":"Bronchodilators for Wheeze in Young Children Presenting to Primary Care: a Randomised, Placebo-controlled, Multicentre, Parallel Group Trial","status":"WITHDRAWN","sponsor":"UMC Utrecht","startDate":"2021-09","conditions":"Wheezing","enrollment":""},{"nctId":"NCT03474081","phase":"PHASE4","title":"A Comparative Study Between Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy Versus Tiotropium Monotherapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-03-29","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":800},{"nctId":"NCT03345407","phase":"PHASE2","title":"Dose Finding Study of Nemiralisib (GSK2269557) in Subjects With an Acute Moderate or Severe Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2017-11-28","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":943},{"nctId":"NCT04488705","phase":"PHASE1","title":"A First in Human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of Inhaled ETD002 in Healthy Subjects","status":"COMPLETED","sponsor":"Enterprise Therapeutics Ltd","startDate":"2020-08-13","conditions":"Healthy","enrollment":80},{"nctId":"NCT03098680","phase":"PHASE1","title":"A Study of the Pharmacokinetic and Pharmacodynamic Responses in Healthy and Altered Human Cardiovascular Systems","status":"TERMINATED","sponsor":"Cambridge University Hospitals NHS Foundation Trust","startDate":"2017-04-24","conditions":"Drug-Related Side Effects and Adverse Reactions, Cardiovascular System Disease","enrollment":18},{"nctId":"NCT03287310","phase":"PHASE1","title":"First Time in Human (FTIH) Study to Evaluate Safety, Tolerability, Immunogenicity, Pharmacokinetics (PK) and Pharmacodynamics (PD) of GSK3511294 Administered Subcutaneously (SC) in Subjects With Mild to Moderate Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-10-17","conditions":"Asthma","enrollment":50},{"nctId":"NCT04750603","phase":"PHASE4","title":"Effect of Fluticasone Furoate/Vilanterol on EIA in Adolescents","status":"COMPLETED","sponsor":"Rambam Health Care Campus","startDate":"2018-12-01","conditions":"Asthma in Children","enrollment":92},{"nctId":"NCT03528577","phase":"PHASE3","title":"A Study to Evaluate the Effect of of Albuterol Sulfate Inhalation Aerosol, eq 90 mcg Base (Sun Pharmaceuticals Industries Limited)","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries Limited","startDate":"2018-09-22","conditions":"Asthma","enrollment":128},{"nctId":"NCT04615611","phase":"NA","title":"Physiologic Performance Response to Salbutamol","status":"UNKNOWN","sponsor":"University of Copenhagen","startDate":"2020-11-07","conditions":"Healthy","enrollment":20},{"nctId":"NCT03902106","phase":"NA","title":"Physiological Response to Salbutamol and Exercise","status":"UNKNOWN","sponsor":"University of Copenhagen","startDate":"2019-03-28","conditions":"Healthy","enrollment":40},{"nctId":"NCT03012061","phase":"PHASE2","title":"Phase IIb Study of Umeclidinium (UMEC) Bromide Versus Placebo in Subjects With Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-01-25","conditions":"Asthma","enrollment":425},{"nctId":"NCT03478696","phase":"PHASE4","title":"A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC /VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-06-25","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":732},{"nctId":"NCT03478683","phase":"PHASE4","title":"A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-06-25","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":729},{"nctId":"NCT03170232","phase":"PHASE2","title":"A Pilot Study of Danirixin for Disease Progression in Chronic Obstructive Pulmonary Disease (COPD)","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2017-10-16","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":54},{"nctId":"NCT02573870","phase":"PHASE2","title":"Batefenterol/Fluticasone Furoate in Treatment of Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-12-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":63},{"nctId":"NCT01892488","phase":"PHASE4","title":"Study to Demonstrate That Antibiotics Are Not Needed in Moderate Acute Exacerbations of COPD","status":"COMPLETED","sponsor":"Hannover Medical School","startDate":"2013-06-07","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":295},{"nctId":"NCT02483975","phase":"PHASE3","title":"Effect of Fluticasone Furoate Inhalation Powder on the Hypothalamic-pituitary-adrenocortical Axis of Children Aged 5-11 Years With Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-10-09","conditions":"Asthma","enrollment":111},{"nctId":"NCT03514615","phase":"PHASE1","title":"A Trial to Assess the Safety and Efficacy of Topical Salbutamol in Healthy Volunteers.","status":"COMPLETED","sponsor":"University Hospitals, Leicester","startDate":"2018-01-10","conditions":"Scarring","enrollment":45},{"nctId":"NCT03034915","phase":"PHASE4","title":"A 24-week Study to Compare Umeclidinium/Vilanterol (UMEC/VI), UMEC and Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-06-16","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":2696},{"nctId":"NCT03207243","phase":"PHASE2","title":"Efficacy and Safety Study of GSK3772847 in Subjects With Moderately Severe Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-09-14","conditions":"Asthma","enrollment":165},{"nctId":"NCT03620422","phase":"NA","title":"Mannitol-Induced Cough Challenge in Healthy Controls and Subjects With Mild Allergic Asthma","status":"COMPLETED","sponsor":"McMaster University","startDate":"2019-01-11","conditions":"Asthma, Cough","enrollment":40},{"nctId":"NCT04208581","phase":"PHASE3","title":"Yiqi Huoxue Huatan Granule for Reducing Mortality in COPD With Chronic Respiratory Failure","status":"UNKNOWN","sponsor":"Peking University People's Hospital","startDate":"2019-10-08","conditions":"Chronic Obstructive Pulmonary Disease, Chronic Respiratory Failure","enrollment":372},{"nctId":"NCT01388595","phase":"PHASE4","title":"Fluticasone and Salmeterol in Allergic Rhinitis","status":"COMPLETED","sponsor":"University of Dundee","startDate":"2006-11","conditions":"Allergic Rhinitis","enrollment":23},{"nctId":"NCT02528214","phase":"PHASE3","title":"Evaluation of Dupilumab in Patients With Severe Steroid Dependent Asthma","status":"COMPLETED","sponsor":"Sanofi","startDate":"2015-10-15","conditions":"Asthma","enrollment":210},{"nctId":"NCT02478398","phase":"PHASE3","title":"Efficacy and Safety Study of RAGWITEK™ (MK-3641) in Children With Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (MK-3641-008)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-07-20","conditions":"Rhinitis, Allergic, Seasonal","enrollment":1025},{"nctId":"NCT02371629","phase":"PHASE4","title":"A Study of the Efficacy and Safety of NVA237 in Patients With Moderate to Severe COPD","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2015-06-24","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":776},{"nctId":"NCT02624505","phase":"PHASE3","title":"Pharmacodynamic Bioequivalence of Metered Dose Inhalers of Albuterol Sulfate in Patients With Stable Mild Asthma","status":"COMPLETED","sponsor":"Cipla Ltd.","startDate":"2015-12","conditions":"Bronchial Asthma","enrollment":110},{"nctId":"NCT03364608","phase":"PHASE2","title":"Study to Compare PT007 to Placebo MDI and Open-Label Proventil® HFA in Adult and Adolescent Subjects With Asthma","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2017-12-15","conditions":"Asthma","enrollment":86},{"nctId":"NCT02729051","phase":"PHASE3","title":"Comparative Study of Fluticasone Furoate(FF)/Umeclidinium Bromide (UMEC)/ Vilanterol (VI) Closed Therapy Versus FF/VI Plus UMEC Open Therapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-06-29","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":1055},{"nctId":"NCT01885936","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of Albuterol in Individuals With Late-onset Pompe Disease","status":"COMPLETED","sponsor":"Duke University","startDate":"2013-06","conditions":"Pompe Disease","enrollment":16},{"nctId":"NCT02496715","phase":"PHASE3","title":"Randomized, Placebo-controlled Study Comparing Efficacy of Fluticasone/Salmeterol Combination to Advair in Asthmatics","status":"WITHDRAWN","sponsor":"Actavis Inc.","startDate":"2015-09","conditions":"Asthma","enrollment":""},{"nctId":"NCT02794480","phase":"PHASE4","title":"Phase IV Study in Asthma Subjects for Dry Powder Inhaler (DPI) Versus (vs) Metered Dose Inhaler (MDI) Correct Use","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-08-22","conditions":"Asthma","enrollment":324},{"nctId":"NCT00784758","phase":"NA","title":"Fenzian Asthma Multicenter Outcomes Study","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2009-02","conditions":"Asthma","enrollment":81},{"nctId":"NCT02872597","phase":"PHASE1","title":"Phase I, Placebo-Controlled, Blinded Pilot Study of Ipratropium in Children Admitted to the ICU With Status Asthmaticus","status":"COMPLETED","sponsor":"University Hospitals Cleveland Medical Center","startDate":"2016-09-05","conditions":"Status Asthmaticus","enrollment":30},{"nctId":"NCT01070225","phase":"PHASE4","title":"Reversal of Acute β-Blocker Induced Bronchoconstriction","status":"COMPLETED","sponsor":"University of Dundee","startDate":"2010-03","conditions":"Asthma","enrollment":14}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1035,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo to salbutamol","genericName":"Placebo to salbutamol","companyName":"Novartis","companyId":"novartis","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Salbutamol is a beta-2 adrenergic agonist that relaxes airway smooth muscle by activating beta-2 receptors, causing bronchodilation. Used for Acute bronchospasm relief in asthma, Acute bronchospasm relief in chronic obstructive pulmonary disease (COPD).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}